Nieves Martinez Lago, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, shared a post on X:
“CLDN18.2 in GC.
Beyond zolbetuximab:
- Next-generation mAbs
- ADCs
- Bispecific antibodies
- CAR-T cells
A concise review of the evolving CLDN18.2 therapeutic landscape – and the challenges ahead.”
Title: Precision targeting of CLDN18.2: A new therapeutic paradigm for gastric cancer
Authors: Wei Zhoua, Wuxuan Meib and Changchun Zengc.
Other articles about GI Oncology on OncoDaily.